Analysts who follow the start-up drugmaker think its stock has a chance to soar, but that doesn't mean it's right for you.
/AMGEN%20Inc_%20logo%20on%20meds-by%20Melnikov%20Dmitriy%20via%20Shutterstock.jpg)
Amgen has outperformed the S&P 500, and analysts remain optimistic about the stock’s prospects because of the positive Phase 2 clinical trial data of its obesity drug MariTide.
Structure Therapeutics has a long way to go before beating Wegovy.
Novo Nordisk's stock may not look all that expensive when you're focusing on the long-term potential.
With weight-loss drugs gaining traction, which biopharma stock wins?
Short-term thinking is creating an intriguing opportunity for investors.
The market for treating chronic kidney disease is nearly within reach.
There's new evidence suggesting the drug will find another large market.
The market for anti-obesity drugs is massive one, worth potentially $100 billion or more based on some ...
These two drugmakers have a lot more in common than their market-beating potential.